Scholarlink

Introduction <p>Hematologic response is well established in systemic light chain (AL) amyloidosis treatment, but hepatic response patterns remain unclear. This study explored hepatic response dynamics in hepatic-involved patients with AL amyloidosis who achieved hematologic partial response within 24&#xa0;months post-treatment.</p> Methods <p>Using two- and four-level hepatic response criteria (two-level: hepatic organ response [hepatic OR], hepatic no response [hepatic NR]; four-level: hepatic complete response [hepaCR], hepatic very good partial response [hepaVGPR], hepatic partial response [hepaPR], hepatic no response [hepaNR]), responses were assessed at 3, 6, 12, and 24&#xa0;months.</p> Results <p>Among 137 patients (median follow-up: 55.0&#xa0;months), hepatic OR and ≥ hepaPR plateaued at 24&#xa0;months, with hepatic OR achieved in 75.6% (65/86), hepaCR in 10.5% (9/86), hepaVGPR in 16.3% (14/86), and hepaPR in 38.4% (33/86). The two-level hepatic response better predicted overall survival than the four-level criteria. Patients achieving hepatic OR within 24&#xa0;months had significantly better prognosis than non-responders (log-rank <i>p</i> = 0.008; HR, 2.782; 95% CI, 1.260–6.141), with no impact from response speed. Hematologic complete response (CR<sub>H</sub>) at 3&#xa0;months predicted higher likelihood of 24-month hepatic OR (OR 2.571, 95% CI, 1.387–4.767, <i>p</i> = 0.003).</p> Conclusion <p>The study highlights the importance of monitoring hepatic response dynamics, identifying 3-month CR<sub>H</sub> and 24-month hepatic OR as key treatment milestones.</p> <p>A graphical abstract is also available with this article.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study

  • 期刊论文

  • 发表日期：

    2026年1月12日

查看全文
  • Chengyang Xu,
  • Ai Guan,
  • Lu Zhang,
  • Zhuang Tian,
  • Daobin Zhou,
  • Kai Sun,
  • Kaini Shen,
  • Jian Li

摘要

Introduction

Hematologic response is well established in systemic light chain (AL) amyloidosis treatment, but hepatic response patterns remain unclear. This study explored hepatic response dynamics in hepatic-involved patients with AL amyloidosis who achieved hematologic partial response within 24 months post-treatment.

Methods

Using two- and four-level hepatic response criteria (two-level: hepatic organ response [hepatic OR], hepatic no response [hepatic NR]; four-level: hepatic complete response [hepaCR], hepatic very good partial response [hepaVGPR], hepatic partial response [hepaPR], hepatic no response [hepaNR]), responses were assessed at 3, 6, 12, and 24 months.

Results

Among 137 patients (median follow-up: 55.0 months), hepatic OR and ≥ hepaPR plateaued at 24 months, with hepatic OR achieved in 75.6% (65/86), hepaCR in 10.5% (9/86), hepaVGPR in 16.3% (14/86), and hepaPR in 38.4% (33/86). The two-level hepatic response better predicted overall survival than the four-level criteria. Patients achieving hepatic OR within 24 months had significantly better prognosis than non-responders (log-rank p = 0.008; HR, 2.782; 95% CI, 1.260–6.141), with no impact from response speed. Hematologic complete response (CRH) at 3 months predicted higher likelihood of 24-month hepatic OR (OR 2.571, 95% CI, 1.387–4.767, p = 0.003).

Conclusion

The study highlights the importance of monitoring hepatic response dynamics, identifying 3-month CRH and 24-month hepatic OR as key treatment milestones.

A graphical abstract is also available with this article.